Neuropace/$NPCE
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
- Ticker
- $NPCE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 220
- Headquarters
- Mountain View, United States
- Website
- www.neuropace.com
Neuropace Metrics
BasicAdvanced
$503M
-
-$0.57
1.94
-
Price and volume
Market cap
$503M
Beta
1.94
52-week high
$19.60
52-week low
$8.17
Average daily volume
209K
Financial strength
Current ratio
4.944
Quick ratio
3.822
Long term debt to equity
569.511
Total debt to equity
588.496
Interest coverage (TTM)
-1.92%
Profitability
EBITDA (TTM)
-11.877
Gross margin (TTM)
77.38%
Net profit margin (TTM)
-17.86%
Operating margin (TTM)
-11.34%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-7.47%
Return on equity (TTM)
-103.27%
Valuation
Price to revenue (TTM)
4.596
Price to book
42.24
Price to tangible book (TTM)
42.24
Price to free cash flow (TTM)
-42.357
Free cash flow yield (TTM)
-2.36%
Free cash flow per share (TTM)
-0.346
Growth
Revenue change (TTM)
33.16%
Earnings per share change (TTM)
-32.16%
3-year revenue growth (CAGR)
24.89%
3-year earnings per share growth (CAGR)
-30.50%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.